Amantadine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for amantadine hydrochloride and what is the scope of freedom to operate?
Amantadine hydrochloride
is the generic ingredient in five branded drugs marketed by Zydus, Supernus Pharms, Actavis Elizabeth, Alembic, Bionpharma, Chartwell Molecular, Heritage Pharma, Humanwell Puracap, Invagen Pharms, Rising, Rubicon, Sandoz, Strides Pharma, Upsher Smith Labs, Watson Labs, Watson Labs Inc, Zydus Pharms, Solvay, Endo Pharms, Aurobindo Pharma Usa, Chartwell Rx, Cmp Pharma Inc, Elysium, Endo Operations, G And W Labs Inc, Pharm Assoc, Teva Pharms, Xttrium Labs Inc, Adaptis, Athem, Jubilant Generics, and Zhejiang Jutai Pharm, and is included in forty-two NDAs. There are thirty patents protecting this compound. Additional information is available in the individual branded drug profile pages.Amantadine hydrochloride has forty-six patent family members in eleven countries.
There are five drug master file entries for amantadine hydrochloride. Thirty-three suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for amantadine hydrochloride
International Patents: | 46 |
US Patents: | 30 |
Tradenames: | 5 |
Applicants: | 32 |
NDAs: | 42 |
Drug Master File Entries: | 5 |
Finished Product Suppliers / Packagers: | 33 |
Raw Ingredient (Bulk) Api Vendors: | 154 |
Clinical Trials: | 114 |
Patent Applications: | 2,684 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for amantadine hydrochloride |
What excipients (inactive ingredients) are in amantadine hydrochloride? | amantadine hydrochloride excipients list |
DailyMed Link: | amantadine hydrochloride at DailyMed |
Recent Clinical Trials for amantadine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ohio State University | Phase 1 |
Ain Shams University | Phase 3 |
Shahid Beheshti University of Medical Sciences | Phase 2 |
Generic filers with tentative approvals for AMANTADINE HYDROCHLORIDE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | EQ 68.5MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for amantadine hydrochloride
Drug Class | Influenza A M2 Protein Inhibitor |
Mechanism of Action | M2 Protein Inhibitors |
Medical Subject Heading (MeSH) Categories for amantadine hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for amantadine hydrochloride
Paragraph IV (Patent) Challenges for AMANTADINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
GOCOVRI | Extended-release Capsules | amantadine hydrochloride | 68.5 mg | 208944 | 1 | 2020-04-30 |
GOCOVRI | Extended-release Capsules | amantadine hydrochloride | 137 mg | 208944 | 1 | 2018-01-16 |
US Patents and Regulatory Information for amantadine hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Invagen Pharms | AMANTADINE HYDROCHLORIDE | amantadine hydrochloride | TABLET;ORAL | 207571-001 | Jan 31, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Supernus Pharms | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Adaptis | AMANTADINE HYDROCHLORIDE | amantadine hydrochloride | TABLET;ORAL | 212407-001 | May 27, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for amantadine hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for amantadine hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1845968 | COMPOSITION ET METHODE POUR TRAITER DES AFFECTIONS NEUROLOGIQUES (COMPOSITION COMPRISING AN NMDA RECEPTOR ANTAGONIST AND LEVODOPA AND USE THEREOF FOR TREATING NEUROLOGICAL DISEASE) | ⤷ Sign Up |
European Patent Office | 2506709 | COMPOSITIONS D'AMANTADINE ET PROCÉDÉS D'UTILISATION ASSOCIÉS (AMANTADINE COMPOSITIONS AND METHODS OF USE) | ⤷ Sign Up |
Mexico | 2012006320 | COMPOSICIONES DE AMANTADINA Y METODOS PARA SU USO. (AMANTADINE COMPOSITIONS AND METHODS OF USE.) | ⤷ Sign Up |
European Patent Office | 3672581 | COMPOSITIONS D'AMANTADINE, LEURS PRÉPARATION, ET PROCÉDÉS D'UTILISATION (AMANTADINE COMPOSITIONS, PREPARATIONS THEREOF, AND METHODS OF USE) | ⤷ Sign Up |
Japan | 2015131818 | アマンタジン組成物および使用方法 (AMANTADINE COMPOSITIONS AND METHODS OF USE) | ⤷ Sign Up |
European Patent Office | 1834638 | DISPOSITIF OSMOTIQUE CONTENANT DE L'AMANTADINE ET UN SEL OSMOTIQUE (OSMOTIC DEVICE CONTAINING AMANTADINE AND AN OSMOTIC SALT) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.